A Next-generation Biologic, Ixekizumab in the Management of Psoriasis -Pharmacology, Efficacy, and Safety Profile of Ixekizumab in Patients with Psoriasis-

Abstract

Ixekizumab targets IL-17A, which plays a vital role in the pathogenesis of psoriasis. Results from multinational, randomized, double-blinded, placebo-controlled, parallel-group studies showed that, after 12 weeks treatment with ixekizumab, psoriasis area and severity index (PASI) 75 response rate was 77.5% to 89.7%, PASI 90 response rate 59.7% to 70.9%, and PASI 100 response rate 30.8% to 40.5%, respectively in patients with plaque psoriasis. In an open-label single-arm study in Japan, PASI 75, 90 and 100 response rates were 98.7%, 83.3% and 32.1%. Ixekizumab also showed efficacy in patients with psoriatic arthritis, erythrodermic psoriasis, and pustular psoriasis. The safety profile of ixekizumab was similar to that of other biologic agents; thus, it is considered that ixekizumab treatment can be safely managed. In this article, we summarize the pharmacological properties, efficacy, and safety of ixekizumab.